Researchers in the U.K. will soon begin testing a drug that they say may be the breakthrough for Alzheimer’s Disease and other dementia that the world awaits. The drug, Liraglutide, is already on the market as a treatment for diabetes.
The Imperial College London and the Addenbrooke’s Hospital in Cambridge are partnering on the research and are looking for volunteers with early onset dementia to partake in a study of Liraglutide. They will need to recruit 200 people of both sexes in their 50s who have been diagnosed with Alzheimer’s. The trial will last one year and brain testing is involved.
“We’re hoping this will improve the memory function in people and their quality of life,” Dr Paul Edison, lead author of the study, told media. “We’re hoping we will be able to delay the progression of the disease.”
The drug increases the production of insulin — hence its use in diabetes — and researchers say the increase in insulin helps to not only protect the brain but repair neurons which have a build-up of amyloid beta plaques, which causes Alzheimer’s. The drug is able to do this because, unlike other drugs, it can pass through the blood-brain barrier.
Lancaster University tested Liraglutide on mice who’d been given dementia and published the results in 2013. That research, lead by Prof. Christian Hölscher, found a daily dose reduced the amyloid plaque build-up in their brains. As a result the memories of the mice improved.
Read more: Alzheimer’s breakthrough drug may ‘dramatically change’ treatment
The Latest on: Liraglutide
[google_news title=”” keyword=”Liraglutide” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liraglutide
- Love Island’s Shaughna Phillips goes make-up free on a walk with daughter after revealing weight loss transformationon May 1, 2024 at 7:22 am
LOVE Island star Shaughna Phillips showed off dramatic weight loss transformation as she enjoyed a stroll with her daughter. The ITV2 contestant, 30, nattered away on her phone as she stepped out ...
- FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugson May 1, 2024 at 5:02 am
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their ...
- FTC steps up campaign on junk patents with warning letterson May 1, 2024 at 2:05 am
Boehringer Ingelheim, GSK, Novartis, Teva, and Covis Pharma have been taken to task for asthma and COPD inhalers, while Amphastar Pharma has been warned over its Baqsimi glucagon nasal spray, used to ...
- Weight loss treatments bring in billions but capacity remains an issueon April 30, 2024 at 5:00 pm
The company’s previous generation weight loss drug, Saxenda (liraglutide), did not sell particularly well – though, revenues have since taken off due to the popularity of the second-generation of ...
- These 10 Weight Loss Drugs Like Ozempic Can Work, but Are They Safe?on April 30, 2024 at 11:30 am
Research has shown some benefits to different types of weight loss drugs. Here’s how they work — and the potential side effects to be aware of.
- Liraglutide Weight Loss - Top 6 Safer and Cheapest Liraglutide Substitutes Over the Counter Optionson April 30, 2024 at 6:33 am
FitSpresso emerged as a noteworthy alternative to Liraglutide, championing natural ingredients scientifically proven to enhance the body's fat-burning capabilities. Its unique blend, including ...
- Is Ozempic the New Anti-Inflammatory Wonder Drug?on April 30, 2024 at 4:00 am
Some GLP-1s are now FDA approved for chronic weight management, including Wegovy (semaglutide) and Saxenda (liraglutide), while others like Ozempic (semaglutide) are approved for type 2 diabetes but ...
- LEXX: Begin with the End in Mindon April 29, 2024 at 7:31 am
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2024 results along with program updates, progress in its GLP-1 and hypertension ...
- Novo Nordisk: Growth Is Still A Better Choiceon April 29, 2024 at 6:59 am
Moreover, Novo Nordisk management expects its total sales in 2024 to grow by 18% to 26% relative to 2023, even in the face of increased competition in the global insulin market, as well as the ...
- From ‘curing’ snoring to warding off dementia – all the surprising ways weight-loss jabs can BOOST your healthon April 29, 2024 at 4:46 am
IT’S impossible to escape the hype around weight-loss jabs. Whether that be the wild before-and-after pictures flooding social media. Or the feral gossip that follows everytime a celebrity ...
via Bing News
